The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Symmetry Medical beat expectations on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue shrank, and GAAP earnings per share shrank to a loss.
Margins shrank across the board.
Symmetry Medical logged revenue of $84.5 million. The two analysts polled by S&P Capital IQ predicted net sales of $80 million on the same basis. GAAP reported sales were 12% lower than the prior-year quarter's $96 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.01. The four earnings estimates compiled by S&P Capital IQ forecast $0.04 per share on the same basis. GAAP EPS were -$0.09 for Q4 versus $0.12 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 17.1%, 630 basis points worse than the prior-year quarter. Operating margin was 4.9%, 450 basis points worse than the prior-year quarter. Net margin was -3.8%, 830 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $99.3 million. On the bottom line, the average EPS estimate is $0.09.
Next year's average estimate for revenue is $418.1 million. The average EPS estimate is $0.56.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Symmetry Medical is outperform, with an average price target of $11.25.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Symmetry Medical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Symmetry Medical to My Watchlist.